Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW -- Ignore unavailable to you. Want to Upgrade?

To: Graham Marshman who wrote (204)	6/1/1998 11:02:00 AM
From: Bexar	Read Replies (1) \| Respond to of 857

The Turnaround Letter. Click Here for 30 Day Free Trial Pharmaceutical Materials from South Africa Now in Clinical Use In Europe and USA by Hemispherx Biopharma, Inc. PR Newswire, Monday, June 01, 1998 at 10:25 PHILADELPHIA, June 1 /PRNewswire/ -- Hemispherx Biopharma, Inc. (AMEX:HEB) announced today that pharmaceutical raw materials from Bioclones (PTY) Ltd., Johannesburg, Republic of South Africa have been introduced successfully into its Ampligen(R) drug product being utilized in various clinical trials in the USA and in Europe. The South African materials now are incorporated in some U.S. manufacturing "runs" of Ampligen(R), a ribonucleic (RNA) compound being developed by Hemispherx Biopharma for therapeutic use in various viral infections of man. Ampligen(R) is being used in eight clinical sites in the USA under a treatment protocol approved by the FDA -- and also in Belgium to treat Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME), a severely debilitating disease which afflicts at least 400,000 Americans. Ampligen(R) is the only drug being developed world-wide at the Phase III level for CFS/ME. Formerly relying on raw materials provided by Pharmacia/Upjohn, a strategic manufacturing partner of HEB, Bioclones now is a second approved supplier of the drug raw materials. William A. Carter, M.D., F.A.C.P., Chairman and CEO of Hemispherx Biopharma, stated that: "We are very pleased to welcome Bioclones as an approved supplier. This provides additional assurances to all current patients that their needs will be met in a timely manner. It also assures rapid expansion of supplies to meet our growing global drug requirements." RNA is a group of naturally occurring molecules that can increase cellular defenses against viral diseases. HEB has obtained more than 300 patents in this therapeutic area. Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of HEMISPHERX involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward looking statements. SOURCE Hemispherx Biopharma, Inc. -0- 06/01/98 /CONTACT: William A. Carter, M.D., CEO & Chairman, 215-988-0080, or Sharon Wills, Investor Relations, 212-572-0762, or fax, 212-572-0764, both of Hemispherx Biopharma/ /Web site: hemispherx.com